We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
Geraldine
Hartshorne
+44 (0) 2476 968867
geraldine.hartshorne@warwick.ac.uk
Prof
Geraldine
Hartshorne
+44 (0) 2476 968867
geraldine.hartshorne@warwick.ac.uk
In vitro fertilization (IVF), infertility, miscarriage, chromosomal anomalies arising in female meiosis such as Trisomy 21 Down syndrome, mosaicism
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
This research programme aims to understand molecular events at the beginning of human life. The study team perform basic scientific research that will underpin future improvements to fertility treatments and explain what happens when problems arise, such as genetic abnormalities. To date, they have relied solely upon studying eggs and embryos of insufficient quality for patient treatment, that would otherwise be discarded. Therefore, their results are sometimes challenged as lacking relevance to the ‘normal’ situation.
This study aims to open up a new source of 'high quality', potentially normal human eggs for research use. This study will provide important preliminary evidence about whether 'high quality' eggs differ from the current source and will test the feasibility of the study team's procedures.
This new arrangement benefits the research in two ways: first, providing ‘gold standard’ control eggs, most likely to be ‘normal’, against which to compare results with eggs derived from other sources. Second, it demonstrates the ability to source good quality eggs from young women. The study team are currently engaged in other funding applications and research plans. Having a source of 'high quality' research eggs strengthens applications and demonstrates capacity as well as increasing the robustness of the research conducted.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
2020 Preprint results in https://doi.org/10.1101/2020.07.17.208744 non-peer-reviewed first results in preprint
You can take part if:
You may not be able to take part if:
The exclusion criteria are the same as those applied clinically for patients sharing eggs with another person/couple.1. Not in the required age range or BMI range2. History of previous poor ovarian response or evidence of low ovarian reserve3. Previous pregnancy loss due to fetal abnormality4. Family history of inherited disease5. Positive test results for viral risks (Human Immunodeficiency Virus [HIV], Hepatitis B, Hepatitis C, or Zika virus) or transmissible diseases6. Medical contraindication to ovarian stimulation or oocyte recovery7. Hydrosalpinges or large endometriotic ovarian cysts8. Previous history of adverse embryology9. Unwilling to have all screening tests10. Unwilling to have independent counselling11. Unwilling to consent to the research project
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Prof
Geraldine
Hartshorne
+44 (0) 2476 968867
geraldine.hartshorne@warwick.ac.uk
Prof
Geraldine
Hartshorne
+44 (0) 2476 968867
geraldine.hartshorne@warwick.ac.uk
The study is sponsored by University of Warwick and funded by WPH Charitable Trust; Wellcome Trust.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
